114 related articles for article (PubMed ID: 19441893)
1. Naked siLNA-mediated gene silencing of lung bronchoepithelium EGFP expression after intravenous administration.
Glud SZ; Bramsen JB; Dagnaes-Hansen F; Wengel J; Howard KA; Nyengaard JR; Kjems J
Oligonucleotides; 2009 Jun; 19(2):163-8. PubMed ID: 19441893
[TBL] [Abstract][Full Text] [Related]
2. An inhalable β₂-adrenoceptor ligand-directed guanidinylated chitosan carrier for targeted delivery of siRNA to lung.
Luo Y; Zhai X; Ma C; Sun P; Fu Z; Liu W; Xu J
J Control Release; 2012 Aug; 162(1):28-36. PubMed ID: 22698944
[TBL] [Abstract][Full Text] [Related]
3. Histological Quantification of Gene Silencing by Intratracheal Administration of Dry Powdered Small-Interfering RNA/Chitosan Complexes in the Murine Lung.
Ihara D; Hattori N; Horimasu Y; Masuda T; Nakashima T; Senoo T; Iwamoto H; Fujitaka K; Okamoto H; Kohno N
Pharm Res; 2015 Dec; 32(12):3877-85. PubMed ID: 26138669
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo.
Mook OR; Baas F; de Wissel MB; Fluiter K
Mol Cancer Ther; 2007 Mar; 6(3):833-43. PubMed ID: 17363479
[TBL] [Abstract][Full Text] [Related]
5. Poly(lactide-
Wu L; Wu LP; Wu J; Sun J; He Z; Rodríguez-Rodríguez C; Saatchi K; Dailey LA; Häfeli UO; Cun D; Yang M
ACS Appl Mater Interfaces; 2021 Jan; 13(3):3722-3737. PubMed ID: 33439616
[TBL] [Abstract][Full Text] [Related]
6. Efficient gene silencing in lungs and liver using imidazole-modified chitosan as a nanocarrier for small interfering RNA.
Ghosn B; Singh A; Li M; Vlassov AV; Burnett C; Puri N; Roy K
Oligonucleotides; 2010 Jun; 20(3):163-72. PubMed ID: 20565242
[TBL] [Abstract][Full Text] [Related]
7. The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing.
Liu X; Howard KA; Dong M; Andersen MØ; Rahbek UL; Johnsen MG; Hansen OC; Besenbacher F; Kjems J
Biomaterials; 2007 Feb; 28(6):1280-8. PubMed ID: 17126901
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary gene silencing in transgenic EGFP mice using aerosolised chitosan/siRNA nanoparticles.
Nielsen EJ; Nielsen JM; Becker D; Karlas A; Prakash H; Glud SZ; Merrison J; Besenbacher F; Meyer TF; Kjems J; Howard KA
Pharm Res; 2010 Dec; 27(12):2520-7. PubMed ID: 20824309
[TBL] [Abstract][Full Text] [Related]
9. Chitosan Nanoparticles for SiRNA Delivery In Vitro.
Ragelle H; Vanvarenberg K; Vandermeulen G; Préat V
Methods Mol Biol; 2016; 1364():143-50. PubMed ID: 26472448
[TBL] [Abstract][Full Text] [Related]
10. [Chitosan-siRNA complex nanoparticles for gene silencing].
Liu X
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2010 Feb; 27(1):97-101. PubMed ID: 20337033
[TBL] [Abstract][Full Text] [Related]
11. RNAi-mediated suppression of constitutive pulmonary gene expression by small interfering RNA in mice.
Gutbier B; Kube SM; Reppe K; Santel A; Lange C; Kaufmann J; Suttorp N; Witzenrath M
Pulm Pharmacol Ther; 2010 Aug; 23(4):334-44. PubMed ID: 20362688
[TBL] [Abstract][Full Text] [Related]
12. siRNA delivery with chitosan nanoparticles: Molecular properties favoring efficient gene silencing.
Malmo J; Sørgård H; Vårum KM; Strand SP
J Control Release; 2012 Mar; 158(2):261-8. PubMed ID: 22119955
[TBL] [Abstract][Full Text] [Related]
13. Comparative in vivo study of poly(ethylene imine)/siRNA complexes for pulmonary delivery in mice.
Beyerle A; Braun A; Merkel O; Koch F; Kissel T; Stoeger T
J Control Release; 2011 Apr; 151(1):51-6. PubMed ID: 21223987
[TBL] [Abstract][Full Text] [Related]
14. Chemically modified oligonucleotide-increased stability negatively correlates with its efficacy despite efficient electrotransfer.
Pelofy S; Teissié J; Golzio M; Chabot S
J Membr Biol; 2012 Sep; 245(9):565-71. PubMed ID: 22797942
[TBL] [Abstract][Full Text] [Related]
15. Nonviral pulmonary delivery of siRNA.
Merkel OM; Kissel T
Acc Chem Res; 2012 Jul; 45(7):961-70. PubMed ID: 21905687
[TBL] [Abstract][Full Text] [Related]
16. Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense.
Moschos SA; Frick M; Taylor B; Turnpenny P; Graves H; Spink KG; Brady K; Lamb D; Collins D; Rockel TD; Weber M; Lazari O; Perez-Tosar L; Fancy SA; Lapthorn C; Green MX; Evans S; Selby M; Jones G; Jones L; Kearney S; Mechiche H; Gikunju D; Subramanian R; Uhlmann E; Jurk M; Vollmer J; Ciaramella G; Yeadon M
Mol Ther; 2011 Dec; 19(12):2163-8. PubMed ID: 21971426
[TBL] [Abstract][Full Text] [Related]
17. Chitosan nanoparticles for siRNA delivery: optimizing formulation to increase stability and efficiency.
Ragelle H; Riva R; Vandermeulen G; Naeye B; Pourcelle V; Le Duff CS; D'Haese C; Nysten B; Braeckmans K; De Smedt SC; Jérôme C; Préat V
J Control Release; 2014 Feb; 176():54-63. PubMed ID: 24389132
[TBL] [Abstract][Full Text] [Related]
18. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model.
Reich SJ; Fosnot J; Kuroki A; Tang W; Yang X; Maguire AM; Bennett J; Tolentino MJ
Mol Vis; 2003 May; 9():210-6. PubMed ID: 12789138
[TBL] [Abstract][Full Text] [Related]
19. PEGylated carboxymethyl chitosan/calcium phosphate hybrid anionic nanoparticles mediated hTERT siRNA delivery for anticancer therapy.
Xie Y; Qiao H; Su Z; Chen M; Ping Q; Sun M
Biomaterials; 2014 Sep; 35(27):7978-91. PubMed ID: 24939077
[TBL] [Abstract][Full Text] [Related]
20. Nonviral siRNA delivery to the lung: investigation of PEG-PEI polyplexes and their in vivo performance.
Merkel OM; Beyerle A; Librizzi D; Pfestroff A; Behr TM; Sproat B; Barth PJ; Kissel T
Mol Pharm; 2009; 6(4):1246-60. PubMed ID: 19606864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
